Abstract

Diabetic nephropathy, often known as DN, is the condition that is responsible for the majority of diabetes-related cases of chronic kidney disease. Since the 1990s, we have been employing RAAS blocking, which encompasses aldosterone antagonists such as spironolactone and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, in order to delay the progression of diabetic nephropathy. After the advent of novel anti-hyperglycemic drugs, such as SGLT2 (sodium-glucose-linked transporter type 2) inhibitors, the focus of therapy has switched from controlling difficulties to avoiding micro- and macrovascular consequences. This shift in focus has occurred because of the introduction of these therapies. It has been since the introduction of these medications that this shift in strategy has taken place. This modification came about as a consequence of the introduction of these innovative drugs. When it comes to the treatment of type 2 diabetes mellitus (T2DM), chronic kidney disease (as proved by the DAPA-CKD study), and heart failure (as revealed by the DAPA-HF research), dapagliflozin, which is an SGLT2 inhibitor, has been shown to be successful. Due to the fact that, in the context of our setup, no previous study of a comparable kind had been conducted to determine the impact of dapagliflozin on diabetic patients who had been diagnosed with chronic kidney disease (CKD), this investigation was carried out.

Description